PIM1 and breast cancer: In prostate and lung malignancies, acute myeloid leukemia, pancreatic ductal adenocarcinoma, and breast cancer, overexpression of the kinases CK2 and PIM-1 in patient tumors correlates with poor prognosis and is regarded an unfavorable prognostic marker [19–22].